



Institute of Biochemistry II  
University Hospital, Bldg. 75  
Theodor-Stern-Kai 7  
D-60590 Frankfurt, Germany

**Press release from the Institute of Biochemistry II**

**April 5<sup>th</sup>, 2006**

**Ivan Dikic receives 26<sup>th</sup> AACR Award for Outstanding  
Achievement in Cancer Research**

Dr. Ivan Dikic (39), professor at Goethe University Medical School received the 26<sup>th</sup> American Association for Cancer Research (AACR) award for Outstanding Achievement in Cancer Research. The prize was awarded on April 4<sup>th</sup>, 2006 at the annual meeting of AACR in Washington DC. Professor Dikic is the first scientist working in Europe who received this prestigious recognition.

The AACR is the world's oldest and largest society for cancer research. This Award gives recognition to a young investigator (under 40 years of age) on the basis of meritorious achievement in cancer research.

Dr. Dikic is honored for his groundbreaking contribution to the field of growth factor receptor signaling. Through this work, Dr. Dikic has propelled a major advancement of our current understanding of the molecular machinery, which along with the ubiquitylation, controls the intracellular trafficking of ligand-engaged and –activated growth factor receptors. The AACR also credited Dr. Dikic's dedication to the education of young scientists, through active participation in teaching programs and as a founder of the Dubrovnik signaling conference.

Ivan Dikic graduated at the Medical School University of Zagreb, Croatia in 1991. He next joined the laboratory of Dr. Joseph Schlessinger in New York, where he completed his Ph.D. and postdoctoral training (1992-1997). From 1997-2003 Dr. Dikic led a research group at the Ludwig Institute for Cancer Research, Uppsala, Sweden. In 2003, Dr. Dikic was appointed a professor at the Goethe University Medical School in Frankfurt, Germany.

Professor Dikic has published more than 70 scientific manuscripts in prestigious journals and has received a number of international distinctions for his research including the Binder Innovation prize (Braunschweig, 2006), the Fernstrom Price (Lund, 2002), the Swedish Strategic Fund award (Stockholm, 2000), the Boehringer Ingelheim Funds award (Stuttgart, 1997). His current research interests are focused on the emerging role of ubiquitin and Ub-like modifiers as signalling devices controlling intracellular trafficking, gene transcription and DNA repair.

For further information:

Dipl.-Biol. Stefan Kieß  
Presse- und Öffentlichkeitsarbeit  
Institut für Biochemie II  
Universitätsklinikum Frankfurt  
Theodor-Stern-Kai 7  
Tel: (069) 63 01 - 54 50  
E-Mail [kiess@em.uni-frankfurt.de](mailto:kiess@em.uni-frankfurt.de)

web page of the Institute: [www.biochem2.de](http://www.biochem2.de)  
or <http://molsig.biochem2.de>